Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.77 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.77 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.75 |
| ▸ | MAOA | P21397 | 3/20 | 0.73 |
| ▸ | DHODH | Q02127 | 1/20 | 0.66 |
| ▸ | XDH | P47989 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25190973 | 1.00 | MAOB (0.77) | MAOBCYP1B1CXCL12MAOADHODH | |
| SCHEMBL11486412 | 1.00 | MAOB (0.77) | MAOBCYP1B1CXCL12MAOADHODH | |
| SCHEMBL25202083 | 1.00 | MAOB (0.77) | MAOBCYP1B1CXCL12MAOADHODH | |
| 4',4-Dichlorochalcone SCHEMBL659210 | 0.93 | MAOB (0.86) | MAOBCYP1B1CXCL12MAOAF3 | |
| 4',4-Dichlorochalcone SCHEMBL659211 | 0.93 | MAOB (0.86) | MAOBCYP1B1CXCL12MAOAF3 | |
| 4',4-Dichlorochalcone SCHEMBL11819608 | 0.91 | MAOB (0.83) | MAOBCYP1B1CXCL12MAOAF3 | |
| 4',4-Dichlorochalcone SCHEMBL11819257 | 0.91 | MAOB (0.83) | MAOBCYP1B1CXCL12MAOAF3 | |
| 4',4-Dichlorochalcone SCHEMBL11819602 | 0.91 | MAOB (0.83) | MAOBCYP1B1CXCL12MAOAF3 | |
| 4',4-Dichlorochalcone SCHEMBL11819262 | 0.91 | MAOB (0.83) | MAOBCYP1B1CXCL12MAOAF3 | |
| SCHEMBL25201250 | 0.91 | XDH (0.74) | MAOBCYP1B1CXCL12MAOAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-4219477-A | Penicillin derivatives | NIPPON CHEMIPHAR COMPANY LIMITED (JP) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAOB 1004/4885CYP1B1 230/4885CXCL12 399/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885CYP1B1 1027/4885CXCL12 287/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885CYP1B1 1027/4885CXCL12 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.